Trial Profile
A randomized phase I/II trial of bortezomib (Velcade) and allogeneic peripheral blood stem cell or bone marrow transplantation for patients with multiple myeloma or AML/MDS [acute myeloid leukaemia/myelodysplastic syndromes]
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Jul 2006
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 26 Jul 2006 New trial record.